DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Axitinib
Axitinib
The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
Nonclinical Antiangiogenesis And
Study Protocol);
In Vitro Kinetic Characterization of Axitinib Metabolism S
Combination Strategy Targeting VEGF and HGF/C-Met in Human Renal
For Health Professionals Who Care for Cancer Patients
5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors
Neoadjuvant Combination of Pazopanib Or Axitinib And
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
202324Orig1s000
Avelumab in Combination with Axitinib Advanced Renal Cell Carcinoma
(Vismodegib) for Gleevec
Axitinib and Sorafenib Are Potent in Tyrosine Kinase Inhibitor Resistant
Axitinib for Treating Advanced Renal Cell Carcinoma After Failure of Prior Systemic Treatment
Bladder Cancer
Second Line Therapy with Axitinib After
PDF of Antibody News
Top View
California Health & Wellness
PF-00299804 Bosutinib Axitinib
Avelumab 20Mg/Ml Concentrate for Solution for Infusion (Bavencio®) Merck Kgaa/Pfizer
Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
FDA Updates Highlighting the Latest Cancer Treatments
Open Full Page
Pulmonary Arterial Hypertension Associated with Protein Kinase Inhibitors: a Pharmacovigilance- Pharmacodynamic Study
Maximizing Clinical Outcomes with Axitinib Therapy in Advanced Renal Cell Carcinoma Through Proactive Side-Effect Management
Specialty Pharmacy Distribution Network for IBRANCE® (Palbociclib), INLYTA® (Axitinib), XALKORI® (Crizotinib), BOSULIF® (Bosutinib), and SUTENT® (Sunitinib Malate)
ATC/DDD Classification (Final)
INLYTA (Axitinib) Is a Kinase Inhibitor
“I Fight.” “I Was in the Waiting Room
Inlyta, Through the Centralised Procedure Falling Within the Article 3(1) and Point 3 of Annex of Regulation (EC) No 726/2004
Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
Avelumab-Axitinib
Axitinib for the Treatment of Patients with Advanced Metastatic Renal Cell Carcinoma (Mrcc) After Failure of Prior Systemic Treatment
Renal Cell Carcinoma Treatment Regimens
SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020